Half-Year 2022 Financial and Clinical Trials Update
Tecentriq overview: Adjuvant program to read out in 2022/23
CHFM
Tecentriq Q2 update
Roche
Ph III (IMvoke010) in adjuvant SCCHN continues to final analysis
•
YoY CER growth
•
+13%
Japan: Sales impacted by mandatory price cut
1,000
900
800
+31%
+54%
700
600
500
+146%
400
300
200
100
0
Lung franchise (NSCLC, SCLC)
•
.
EU: Approval in adjuvant PDL1+ NSCLC achieved;
Growth driven by 1L SCLC
US: Strong launch in adjuvant PDL 1+ NSCLC
Gl franchise (HCC)
US/EU/Japan: Growth driven by 1L HCC
Outlook 2022
• Further growth due to first-to-market indications
Q2 19
Q2 20
Q2 21
Q222
•
■US Europe
International
Japan
⚫ Ph III Tecentriq adjuvant studies in HCC and neoadjuvant
NSCLC reading out
•
⚫ Ph III tiragolumab + Tecentriq in 1L EC reading out
CER-Constant Exchange Rates; SCCHN-squamous cell carcinoma of the head and neck; NSCLC=non small cell lung cancer; SCLC-small cell lung cancer; HCC-hepatocellular cancer; EC-esophageal cancer
23View entire presentation